Vaxcyte, Inc. (PCVX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 15, 2024, details a material definitive agreement regarding the expansion and consolidation of Vaxcyte, Inc.'s corporate headquarters located at 825 Industrial Road in San Carlos, California. The filing consolidates a previously assumed lease with a new amended and restated lease agreement with the landlord, ARE-San Francisco No. 63, LLC.
Key Financial Metrics and Lease Terms
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to the new lease obligations:
- Total Leased Space: 258,581 rentable square feet (RSF), combining existing and additional premises.
- Security Deposit: $1,091,276.59 (previously provided via letters of credit) now secures the new agreement.
- Base Rent Rates:
- Suite 100A and Suite 200B: $6.026 per RSF/month (3% annual increase).
- Suite 200A and Suite 300: $5.941 per RSF/month (3% annual increase).
- Additional Premises (Suits 400, 500, 600): $6.00 per RSF/month (3% annual increase).
- Rent Abatement: Eight full calendar months of base rent abatement for each Additional Premises following its commencement date.
- Lease Term: 120 months from the first full month following the first Additional Premises commencement, with two optional five-year extensions.
Material Changes and Sublease Activity
The company terminated its prior "Assumed Lease" with Codexis, Inc. and consolidated all space under a single "Amended and Restated Lease." Simultaneously, the company entered into a Sublease Agreement with Iovance Biotherapeutics, Inc. for 16,731 RSF within Suite 100A. This sublease generates offsetting revenue at an initial rate of $5.95 per RSF/month, increasing to $6.1285 per RSF/month after the first anniversary. The sublease term is two years with two conditional one-year extension options.
Outlook and Phased Commencement
The expansion of the headquarters will occur in phases. Target commencement dates for the new space are:
- Suite 400A: On or before February 10, 2025.
- Suite 400B: On or before November 17, 2025.
- Suite 500: On or before December 16, 2025.
- Suite 600: On or before June 1, 2026.
The filing notes that the company is responsible for maintenance costs, taxes, and operating expenses in addition to base rent. No specific guidance on future financial performance or risks beyond standard lease covenants is provided in this document.
Key Facts for Investor Verification
- Verify the total monthly cash outflow impact once all Additional Premises commence, accounting for the 8-month rent abatement periods.
- Confirm the operational necessity of the 258,581 RSF footprint relative to current headcount and pipeline development needs.
- Monitor the sublease revenue from Iovance Biotherapeutics, Inc. to ensure it offsets a portion of the increased occupancy costs.
- Review the full text of the Amended and Restated Lease (to be filed as an exhibit to the 2024 Form 10-K) for specific termination rights and default provisions.